To the Editor: We appreciate the comments of Lambros et al 1 about our study that reported coexistent genetic alterations of ALK, RET, ROS1, and/or MET in 15 cases of lung adenocarcinoma. 2 It is gratifying that Lambros et al agree with our conclusion that the coexistences of two or more driver mutations are rare but true events in lung adenocarcinoma, although these mutations are historically considered as mutually exclusive. In regard to their concerns about the cutoff values for ROS1 and RET fluorescent in situ hybridization (FISH) tests in our study, the ROS1 and RET FISH tests we report were developed and validated in our clinical diagnostic laboratory by following the American College of Medical Genetics (ACMG) technical standards and guidelines for FISH tests, 3, 4 since there is currently no FDA-approved test/kit for either ROS1 or RET rearrangement available yet. As pointed by Lambros et al, the normal cutoff values for our tests are lower than that reported by other research groups. [5] [6] [7] This is most likely attributable to different statistical methods to generate cutoff values for each abnormal FISH signal pattern in these studies. The confidence interval around the mean (binomial distribution) method was employed in our study. This method usually produce stringent (low) cutoff values, which in turn benefit patients with a truly positive but low-level biomarker to be diagnosed and facilitating their eligibility for a therapeutic intervention (eg, a clinical trial). Presumably, the inverse beta function method that usually produces conservative (high) cutoff values has been utilized in at least a subset of other studies. 3, 4 Although the high cutoff values usually yield very few false-positive results, the possibility of false-negative results is simultaneously increased. As stated by Shan et al, 7 with a cutoff value of ≥ 15% for ROS1 FISH test, 3 of 16 cases with documented ROS1 rearrangement confirmed by both ROS1-immunohistochemistry (IHC) and quantitative real-time reverse transcription-PCR (qRT-PCR) were misdiagnosed as negative by FISH. Similar observations have been made for RET FISH testing as well. 8 Both the ROS1 and RET FISH tests have been re-validated more than twice and calibrated periodically by following the ACMG standards and guidelines in our laboratory. 3, 4 A slight modification of the cut-off values was performed after each re-validation/calibration, but no change of any previous test results for these two biomarkers has been caused consequently. In fact, all cases included in our report 2 have demonstrated an apparent positive result for RET and/or ROS1 rearrangement (eg, positive cells ≥ 15%; Table 1 ). We agree with Lambros et al that a second tier of test(s) such as immunohistochemistry (IHC), qRT-PCR and/or next-generation sequencing (NGS) can be applied to further confirm a positive FISH result, especially for a borderline result, although sometimes results obtained by FISH, IHC, qRT-PCR, and/or NGS may not be concordant. 1, [5] [6] [7] [8] Lambros et al also expressed concern about the high detection rate of triple or even more mutations in the same cases in our study. In addition to coexistent mutations involving ALK, RET, ROS1, or MET, 10 of 15 cases also exhibited mutations of TP53 (n = 6), EGFR (n = 5), KRAS (n = 3), and rarely other genes. We believe that this detection rate is mainly attributable to the utilization of a NGS panel of genes in our study. The EGFR and KRAS mutations were confirmed by Sanger sequencing subsequently, and all 5 patients (cases 1 and 12-15) in our study had received or are receiving EGFR inhibitor treatment. 2 Michels et al 9 reported that 10 of 22 European lung cancer patients with RET-rearrangement also exhibited additional genetic aberrations, 7 with TP53 mutation, 1 with CTNNB mutation, 1 with low level MET amplification, and 1 with both TP53 and EGFR mutations. In their study, an NGS of a panel of 14 genes and Sanger sequencing of selected exons of four genes (EGFR, KRAS, HER2, and BRAF) were performed in 18 and 4 cases, respectively. Therefore, simultaneously testing multiple biomarkers and utilization of the advancing technologies, 
